Antonio Ciaccia

1 week ago | drugtopics.com | Brian Nowosielski |Antonio Ciaccia

Federal investigations, pharmacy community advocacy, and bipartisan support for reform are all just a few things that have contributed to the uncovering of the country’s largest prescription middlemen, or pharmacy benefit managers (PBMs) as people now know them. While they have become scrutinized for their role in the pharmaceutical supply chain, PBMs were once designed to save patients money and keep pharmacies afloat with reimbursable prescription benefits.

2 weeks ago | drugtopics.com | Brian Nowosielski |Antonio Ciaccia

Amidst the often-frictional relationship between PBMs and the pharmacies they reimburse for medication dispensing, there are common misconceptions consistently circulating that have helped fuel PBM scrutiny. “I think pharmacy and pharmacists have arguably a deserved distrust of PBMs and their integrity in fair dealing with them,” said Antonio Ciaccia, President of 3 Axis Advisors and CEO of 46brooklyn Research.

2 weeks ago | drugtopics.com | Brian Nowosielski |Antonio Ciaccia

In part 2 of our interview with Antonio Ciaccia, President of 3 Axis Advisors and CEO of 46brooklyn Research, he explained the history of pharmacy benefit managers (PBMs) and what led them to gain such significant market power. Furthermore, he discussed the many nuances surrounding pharmacy benefits, how PBMs have grown to control drug prices, and why they are now one the most scrutinized entities in all of health care.

2 weeks ago | drugtopics.com | Brian Nowosielski |Antonio Ciaccia

When it comes to pharmacy benefit manager (PBM) reform, pharmacists and industry advocates have been fighting for a change to the way prescription drugs are distributed in the US. The 3 most notable avenues of enacting PBM reform have been identified through legislation, litigation, and market-based solutions. “I think there's 3 main buckets of PBM reform.